Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study
Titel:
Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study
Auteur:
Matsubara, Nobuaki Loriot, Yohann Burgess, Earle F. Park, Se Hoon Huddart, Robert A. Ku, Ja Hyeon Tran, Ben Huang, Jian Huang, Yi-Hsiu Nishimura, Kazuo Shimizu, Nobuaki Xing, Nianzeng Xue, Wei Hemaya, Rosemary Zhuo, Jianmin Deprince, Kris Triantos, Spyros Siefker-Radtke, Arlene O.